Jardiance for adults with congenital heart disease and reduced heart function
Treatments studied
Part of Genetic & congenital, Heart & circulation clinical trials.
This study tests a medicine called Jardiance (an SGLT2 inhibitor) to see if it helps improve heart function in adults with congenital heart disease who have recently experienced a drop in their heart pumping ability. Participants will take the medication alongside standard heart failure treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and were born with a heart defect (congenital heart disease).
- Your congenital heart disease is considered moderate or complex (Level II or III).
- In the last 6 months, your heart’s pumping strength (ejection fraction) has dropped below 60% and decreased by more than 5%, as shown by a heart ultrasound, CT scan, or MRI.
- You do not have diabetes, severe kidney disease (GFR below 20), or certain metabolic conditions.
- You have not taken the study drug (Jardiance) in the last 4 weeks and do not have a history of liver disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well Jardiance works and its safety in Chinese patients with a type of heart failure where the heart pumps normally but doesn't fill properly. It aims to see if this medicine helps these patients feel better and stay out of the hospital.
This trial tests if empagliflozin, a diabetes medicine that also helps the heart, can improve symptoms in children with heart failure. It may help kids with severe symptoms or high levels of a heart stress marker called BNP.
This study tests whether a medicine called an SGLT2 inhibitor (which lowers blood sugar and helps the kidneys) can improve outcomes for people with acute heart failure and kidney problems. Participation involves taking the study drug or a placebo for a short time.
This trial tests whether dapagliflozin, a diabetes drug that also helps the heart, can improve exercise ability and heart function in people who have had the Fontan procedure for a single ventricle heart defect.
This trial is looking at how well Jardiance (a medication for heart failure) works in Chinese patients with a specific type of heart failure called heart failure with reduced ejection fraction. It compares Jardiance to other standard heart failure medications to see which is more effective and safe.
This study tests whether continuing empagliflozin (a heart failure medicine) during a hospital stay for heart failure is beneficial compared to stopping it. Participation may help improve recovery and reduce complications.
Hear when a new Adult Congenital Heart Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.